Shares of Roivant Sciences have moved 1.1% today, and are now trading at a price of $11.97. In contrast, the S&P 500 index saw a 0.0% change. Today's trading volume is 881,514 compared to the stock's average volume of 5,838,588.
Roivant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines and technologies. Based in London, United Kingdom the company has 750 full time employees and a market cap of $8,177,511,936.
The company is now trading -30.02% away from its average analyst target price of $17.11 per share. The 9 analysts following the stock have set target prices ranging from $12.0 to $22.0, and on average give Roivant Sciences a rating of buy.
Over the last 12 months ROIV shares have declined by -1.3%, which represents a difference of -17.0% when compared to the S&P 500. The stock's 52 week high is $13.05 per share and its 52 week low is $8.73. Based on Roivant Sciences's average net margin growth of 29.5% over the last 5 years, its core business remains strong and the stock price may recover in the long term.
| Date Reported | Total Revenue ($ k) | Net Profit ($ k) | Net Margins (%) |
|---|---|---|---|
| 2024 | 29,053 | -171,981 | -592 |
| 2023 | 32,713 | 4,348,926 | |
| 2022 | 31,530 | -1,009,030 | -3200 |
| 2021 | 55,286 | -845,262 | -1529 |
| 2020 | 23,795 | -809,234 | -3401 |
